Garry A. Nicholson - 02 Jun 2025 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Reporting relationship: Director
Issuer ticker: DAWN
Reported as of: 02 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2025, 17:49:02 UTC
Prior SEC filing: 18 Sep 2024
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Charles N. York II, as Attorney-in-Fact

Key filing fact

Garry A. Nicholson filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 04 Jun 2025.

Key facts

This page summarizes Garry A. Nicholson's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Jun 2025, 17:49.

Change

Previous filing in this sequence was filed on 18 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001640861 Primary reporting owner

Nicholson Garry A

Relationship: Director
Address: 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Signature: /s/ Charles N. York II, as Attorney-in-Fact
Signature date: 04 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DAWN transaction Derivative

Stock Option (right to buy Common Stock)

Award

Transaction value: $0
Shares: +22,500
Change %
Price: $0.000000
Shares after: 22,500
Date: 02 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,500
Exercise price: $7.01
Footnotes: F1

DAWN transaction Derivative

Deferred Restricted Stock Unit (RSU)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 02 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.000000
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F3

The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date") , subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan.

Footnote F4

RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.